Brazil's health regulatory agency, Anvisa, has approved a new high-dose formulation of the Wegovy weight-loss injection pen [1].

This approval expands the available therapeutic options for obesity treatment in Brazil. By offering a higher dosage, the agency aims to provide clinicians with tools that may improve the efficacy of the medication for patients who require more intensive treatment.

The newly authorized version of the pen provides a dose of 7.2 mg [1]. This represents a significant increase in potency compared to the range of dosages previously approved by the agency [1].

Prior to this decision, Anvisa had approved several lower dose options for the medication [1]. These previously authorized doses included 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg [1]. The addition of the 7.2 mg option allows for a broader spectrum of patient care, tailoring the medication to individual needs based on response and tolerance.

Anvisa is the national body responsible for overseeing the safety and efficacy of medicines and health products in Brazil [1, 2]. The agency's decision follows a review of the high-dose formulation's profile to ensure it meets national health standards for obesity management [1, 2].

Healthcare providers in Brazil can now integrate this higher dosage into their treatment protocols for patients struggling with obesity [1]. The move reflects a broader trend in pharmaceutical development focusing on dose optimization for GLP-1 receptor agonists to maximize weight loss results [1].

“Anvisa approved a new high‑dose (7.2 mg) formulation of the Wegovy weight‑loss injection pen”

The authorization of a 7.2 mg dose marks a shift toward more aggressive pharmacological interventions for obesity in Brazil. By significantly increasing the maximum available dose beyond the previous 2.4 mg ceiling, Anvisa is acknowledging a need for higher-potency options to achieve therapeutic goals in a diverse patient population.